Treatment of depression -- an update on antidepressant monotherapy and combination therapy.
We analyzed the trends in product regimens used to treat depression to investigate whether there has been a shift in treatment patterns following the May 2008 launch of desvenalfaxine in the United States and the approval of an atypical antipsychotic as add-on therapy to antidepressants. Our analysi...
| Publicado en: | Psychiatry (1550-5952) Vol. 6; no. 8; pp. 15 - 18 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial research Journal Article |
| Publicado: |
Matrix Medical Communications, LLC
Aug2009
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=105434639&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 105434639 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15505952 32GJ jtl: Psychiatry (1550-5952) issn: 15505952 maglogo: N pubinfo: dt: Aug2009 vid: 6 iid: 8 pid: 33670 pub: Matrix Medical Communications, LLC place: West Chester, Pennsylvania artinfo: ui: 105434639 105434639 2010412845 105434639 ppf: 15 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Treatment of depression -- an update on antidepressant monotherapy and combination therapy. aug: au: Lenderts S Kalali A affil: Manager, Strategic Analytics, Quintiles, Inc.,/Innovex, Falls Church, Virginia sug: subj: Antidepressive Agents Antipsychotic Agents Depression Drug Therapy Prescribing Patterns Trends Aripiprazole Drug Therapy, Combination Physicians Psychiatrists Serotonin Uptake Inhibitors Time Factors United States Human ab: We analyzed the trends in product regimens used to treat depression to investigate whether there has been a shift in treatment patterns following the May 2008 launch of desvenalfaxine in the United States and the approval of an atypical antipsychotic as add-on therapy to antidepressants. Our analysis suggests that antidepressant monotherapy continues to be the most widely used drug treatment approach, accounting for 84 percent of depression treatment regimens. Antidepressant monotherapy is more prevalent among primary care physician-prescribed treatment regimens (92%) than psychiatryprescribed regimens (73%). Combination treatment regimens have become increasingly more common as physician perception of disease severity increases, with antidepressant combination therapy accounting for eight percent, 17 percent, and 27 percent of treatment regimens for mild, moderate, and severe depression, respectively. The most commonly used agents in addition to an antidepressant in combination treatment regimens include another antidepressant (40% of combination regimens), an anxiety agent (40%), and/or atypical antipsychotics (18%). A trend analysis suggests that combination regimens that include an antidepressant plus an atypical antipsychotic, anxiety agent, or a prescription sleep aid comprise a greater share of combination regimens in 12 months ending May 2009 than they did in 12 months ending June 2008. pubtype: Academic Journal doctype: pictorial research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|